These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 20929331)

  • 21. Complete remission of Waldenström macroglobulinemia with azacitidine and rituximab.
    Weiss L; Melchardt T; Neureiter D; Kemmerling R; Moshir S; Pleyer L; Greil R; Egle A
    J Clin Oncol; 2011 Aug; 29(24):e696-8. PubMed ID: 21730268
    [No Abstract]   [Full Text] [Related]  

  • 22. Efficacy and long-term toxicity of the rituximab-fludarabine-cyclophosphamide combination therapy in Waldenstrom's macroglobulinemia.
    Souchet L; Levy V; Ouzegdouh M; Tamburini J; Delmer A; Dupuis J; Le Gouill S; Pégourié-Bandelier B; Tournilhac O; Boubaya M; Vargaftig J; Choquet S; Leblond V;
    Am J Hematol; 2016 Aug; 91(8):782-6. PubMed ID: 27135784
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Complete remission of Schnitzler syndrome and Waldenström macroglobulinemia under rituximab-cyclophosphamide-dexamethasone.
    Aouba A; Pressiat C; Pricopi M; Georgin-Lavialle S; Boue F; Lievre-Castilla MA; Marfaing-Koka A; Prevot S; Decottignies A
    Dermatology; 2015; 230(1):18-22. PubMed ID: 25471063
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Waldenström macroglobulinaemia and intestinal lymphangiectasia.
    Cooke RE; Kalnins RM; Ho WK
    Br J Haematol; 2014 Nov; 167(3):292. PubMed ID: 25039993
    [No Abstract]   [Full Text] [Related]  

  • 25. Alkylating Agents in the Treatment of Waldenström Macroglobulinemia.
    Buske C
    Hematol Oncol Clin North Am; 2018 Oct; 32(5):821-827. PubMed ID: 30190020
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of front-line therapy with fludarabine-cyclophosphamide-rituximab regimen for chronic lymphocytic leukemia outside clinical trials: the Israeli CLL Study Group experience.
    Herishanu Y; Goldschmidt N; Bairey O; Ruchlemer R; Fineman R; Rahimi-Levene N; Shvidel L; Tadmor T; Ariel A; Braester A; Shapiro M; Joffe E; Polliack A;
    Haematologica; 2015 May; 100(5):662-9. PubMed ID: 25661442
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Successful treatment of IgM-monoclonal gammopathy of undetermined significance associated with cryoglobulinemia and cold agglutinin disease with immunochemotherapy with rituximab, fludarabine, and cyclophosphamide.
    Bhattacharyya J; Mihara K; Takihara Y; Kimura A
    Ann Hematol; 2012 May; 91(5):797-799. PubMed ID: 21901341
    [No Abstract]   [Full Text] [Related]  

  • 28. How I treat Waldenström macroglobulinemia.
    Treon SP
    Blood; 2015 Aug; 126(6):721-32. PubMed ID: 26002963
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia.
    Treon SP; Branagan AR; Ioakimidis L; Soumerai JD; Patterson CJ; Turnbull B; Wasi P; Emmanouilides C; Frankel SR; Lister A; Morel P; Matous J; Gregory SA; Kimby E
    Blood; 2009 Apr; 113(16):3673-8. PubMed ID: 19015393
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impairment of peripheral blood stem-cell mobilisation in patients with mantle-cell lymphoma following primary treatment with fludarabine and cyclophosphamide +/- rituximab.
    Eve HE; Seymour JF; Rule SA
    Leuk Lymphoma; 2009 Mar; 50(3):463-5. PubMed ID: 19197732
    [No Abstract]   [Full Text] [Related]  

  • 31. Rituximab therapy of severe aplastic anemia induced by fludarabine and cyclophosphamide in a patient affected by B-cell chronic lymphocytic leukemia.
    Castiglioni MG; Scatena P; Pandolfo C; Mechelli S; Bianchi M
    Leuk Lymphoma; 2006 Sep; 47(9):1985-6. PubMed ID: 17065021
    [No Abstract]   [Full Text] [Related]  

  • 32. Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma.
    Tam CS; Wolf M; Prince HM; Januszewicz EH; Westerman D; Lin KI; Carney D; Seymour JF
    Cancer; 2006 Jun; 106(11):2412-20. PubMed ID: 16649223
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin-prednisone in 92 patients with Waldenström macroglobulinemia in first relapse or with primary refractory disease.
    Leblond V; Lévy V; Maloisel F; Cazin B; Fermand JP; Harousseau JL; Remenieras L; Porcher R; Gardembas M; Marit G; Deconinck E; Desablens B; Guilhot F; Philippe G; Stamatoullas A; Guibon O;
    Blood; 2001 Nov; 98(9):2640-4. PubMed ID: 11675332
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rituximab, fludarabine, and cyclophosphamide versus fludarabine and cyclophosphamide for treatment of chronic lymphocytic leukemia: A systematic review with meta-analysis.
    Nunes AA; da Silva AS; Souza KM; Koury Cde N; de Mello LM
    Crit Rev Oncol Hematol; 2015 Jun; 94(3):261-9. PubMed ID: 25797826
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Economic evaluation of rituximab added to fludarabine plus cyclophosphamide versus fludarabine plus cyclophosphamide for the treatment of chronic lymphocytic leukemia].
    Casado LF; García Marco JA; Gilsanz F; González M; Ríos E; de la Serna J; Urbano A; Vicente V; Rubio-Terrés C; Castro AJ
    Gac Sanit; 2011; 25(4):274-81. PubMed ID: 21664727
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Treatment of chronic lymphocytic leukemia with regimen of fludarabine, cyclophosphamide and rituximab].
    Gu WJ; Xu W; Qian SX; Wu YJ; Hong M; Chen LJ; Wu HX; Lu H; Qiu HX; Li JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Aug; 16(4):938-42. PubMed ID: 18718095
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Severe infusion-related reactions are uncommon in rituximab-treated CLL patients in clinical practice: results from a Swedish national observational study.
    Norin S; Björkstrand B; Rommel F; Timberg L; Andersson PO; Häggström J; Aldrin A; Hansson L
    Leuk Res; 2015 Jan; 39(1):33-7. PubMed ID: 25499233
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fludarabine, cyclophosphamide, doxorubicin (FCD), and rituximab: a remission induction therapy for aggressive pediatric post-transplant lymphoproliferative disease (PTLD).
    Giraldi E; Provenzi M; Fiocchi R; Colledan M; Cornelli P; Torre G; Rambaldi A; Conter V
    Pediatr Blood Cancer; 2011 Aug; 57(2):324-8. PubMed ID: 21294246
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.
    Hallek M; Fischer K; Fingerle-Rowson G; Fink AM; Busch R; Mayer J; Hensel M; Hopfinger G; Hess G; von Grünhagen U; Bergmann M; Catalano J; Zinzani PL; Caligaris-Cappio F; Seymour JF; Berrebi A; Jäger U; Cazin B; Trneny M; Westermann A; Wendtner CM; Eichhorst BF; Staib P; Bühler A; Winkler D; Zenz T; Böttcher S; Ritgen M; Mendila M; Kneba M; Döhner H; Stilgenbauer S; ;
    Lancet; 2010 Oct; 376(9747):1164-74. PubMed ID: 20888994
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Early initial therapy of advanced follicular lymphoma: the need for vigilance.
    Sweetenham JW; Freedman AS
    Leuk Lymphoma; 2011 Mar; 52(3):355-7. PubMed ID: 21323517
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.